Physician profile
Gary Bakst
NPI 1275530537
$14,617.83
in general payments reported to CMS, 2019-2025
45 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,603 · 2020: $906 · 2021: $1,654 · 2022: $2,267 · 2023: $2,484 · 2024: $2,431 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,167 · Education: $19.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,166.68 |
| Education | $19.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,581.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,891.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,257.86 | 2019-2025 | Evenity, Tepezza, Prolia |
| Insulet Corporation | $1,199.30 | 2019-2025 | Omnipod |
| Abbott Laboratories | $901.71 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $765.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $692.15 | 2019-2024 | Farxiga, Lokelma |
| Mannkind Corporation | $686.01 | 2019-2025 | Afrezza |
| Dexcom, INC. | $524.47 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $502.97 | 2019-2024 | Synthroid |
| Radius Health, INC. | $464.97 | 2019-2025 | Tymlos |
| Pfizer INC. | $379.30 | 2021-2025 | |
| Corcept Therapeutics | $360.13 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.53 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $265.39 | 2022-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bakst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.